BEIJING (Reuters) – China’s medical products regulator said on Wednesday it has approved the use of BRII Biosciences’ neutrialising antibody cocktail for COVID-19, the first treatment of its type against the disease approved in the country.
The medicine, a combination of BRII-196/BRII-198, was approved to treat mild COVID-19 and the disease of “normal type” with high risk of progressing to hospitalization or death in adults and teenagers aged 12-17, the National Medical Products Administration said in a statement.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Jan Harvey)
